Jefferies Financial Group Inc. Has $1.59 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Jefferies Financial Group Inc. raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 136.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 16,100 shares of the medical equipment provider’s stock after purchasing an additional 9,300 shares during the period. Jefferies Financial Group Inc.’s holdings in Zimmer Biomet were worth $1,586,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Rakuten Investment Management Inc. acquired a new position in Zimmer Biomet during the third quarter worth $37,307,000. Sector Gamma AS grew its holdings in shares of Zimmer Biomet by 28.0% during the third quarter. Sector Gamma AS now owns 113,478 shares of the medical equipment provider’s stock valued at $11,178,000 after buying an additional 24,847 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Zimmer Biomet by 29.2% during the third quarter. SG Americas Securities LLC now owns 61,110 shares of the medical equipment provider’s stock worth $6,019,000 after acquiring an additional 13,812 shares in the last quarter. Border to Coast Pensions Partnership Ltd raised its holdings in shares of Zimmer Biomet by 6.5% in the 3rd quarter. Border to Coast Pensions Partnership Ltd now owns 360,462 shares of the medical equipment provider’s stock worth $35,506,000 after acquiring an additional 22,104 shares during the last quarter. Finally, National Pension Service raised its holdings in shares of Zimmer Biomet by 4.5% in the 3rd quarter. National Pension Service now owns 393,476 shares of the medical equipment provider’s stock worth $38,757,000 after acquiring an additional 16,928 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 2.3%

Shares of NYSE:ZBH opened at $93.82 on Thursday. Zimmer Biomet Holdings, Inc. has a 1 year low of $84.59 and a 1 year high of $114.44. The company has a market capitalization of $18.36 billion, a PE ratio of 26.50, a price-to-earnings-growth ratio of 1.87 and a beta of 0.58. The business has a fifty day moving average price of $92.28 and a two-hundred day moving average price of $95.40. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.98 and a quick ratio of 1.10.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The company had revenue of $2.24 billion for the quarter, compared to analysts’ expectations of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be given a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is currently 27.12%.

Analyst Ratings Changes

A number of analysts have commented on the company. BTIG Research reissued a “buy” rating and set a $112.00 price objective on shares of Zimmer Biomet in a report on Tuesday, February 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, January 21st. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. Wall Street Zen cut shares of Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Finally, Wells Fargo & Company upped their price objective on shares of Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.